In this retrospective cohort study, SUD was not associated with COVID-19-associated inpatient mortality, which was the primary outcome. “The current findings suggest that such an approach might have benefited many patients, including individuals with.

“Early in the pandemic, BMC developed protocols to closely monitor and quickly manage COVID-19-related complications in all hospitalized patients,” Sabrina Assoumou, MD, MPH, an infectious disease doctor at BMC and assistant professor of Medicine at Boston University Chobanian and Avedisian School of Medicine, said in the statement. They compared the likelihood of COVID-19 related complications between individuals with and without SUD.Īdditionally, they compared the relationship among COVID-19 and mortality, clinical complications, and resource utilization. Investigators reviewed medical records of 353 individuals without SUD and 56 with SUD who were admitted to BMC early in the COVID-19 pandemic. In the study, 14% of the study population had SUD, which exceeded the national average of 10.8% of adults. “These findings showing a similar likelihood of COVID-19-related complications in hospitalized patients with and without SUD helps expand knowledge of the infectious complications of SUD,” she said.

Since the early days of the pandemic, BMC has also been a leader in the treatment of individuals with COVID-19, including with complex medical and social needs,” Angela McLaughlin, MD, MPH, an infectious disease fellow at BMC, said in a statement. “BMC is known for excellent clinical care and innovative research related to. Increased risk for severe COVID-19 in individuals with SUD could be from co-occurring medical conditions, investigators said. Substance use disorders (SUDs) were not associated with an increased likelihood of dying from COVID-19, according to the results of a study published in Substance Abuse: Research and Treatment.

Substance 3d